Skyhawk, Biogen Expand Alliance in Neurological Disorders

Skyhawk Therapeutics, Inc. has expanded its collaboration with Biogen, extending Biogen's exclusive license to worldwide rights beyond the original research-stage therapeutic candidates for the treatment of conditions including multiple sclerosis (MS), spinal muscular atrophy (SMA) and additional neurological disorders, leveraging Skyhawk's SkySTAR technology platform.

Skyhawk receives an upfront payment from Biogen and may receive potential future milestone payments and royalties. 

"Biogen is a leading neuro-focused biopharmaceutical company with a compelling history of drug development across a range of challenging conditions," said Bill Haney, co-founder and chief executive officer of Skyhawk. "Their strong scientific culture has already produced a series of leading global therapeutics and our work together to date has gone very well.  We are excited to expand our opportunity to work together to help more patients with challenging unmet medical needs."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com